On June 4, 2026 Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, reported the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Vycellix is attending:
June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo
June 11-14: European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress in Stockholm
June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319)
To request a meeting with Vycellix at any of these events, please contact Doug Calder at [email protected].
Vycellix recently announced the successful completion of pre-clinical development for its universal cell engineering platform (VY-UC) with rigorous studies across many donor cell types proving robust immune evasion with functional persistence. The Company is now preparing for first-in-human clinical validation by seeking regulatory approval in Sweden to initiate a Phase 1 study for its lead VY-UC product candidate, a novel, off-the-shelf NK cell therapy (VNK-101) for patients with relapsed or refractory multiple myeloma.
To view VY-UC mechanism-of-action video, please visit:
The Company has also generated new data in AML and urothelial cancers supporting further development of its VY-GAGE platform and product candidates to engineer persistent allogeneic effector cells capable of delivering multiple disease-targeting payloads directly to tumor sites using logic-gated CARs and proprietary cleavable linkers, which when tumor-activated, deploy potent multi-antigen engagers, CARs and cytokines. This approach is believed to be safer with optimized target engagement and more effective by limiting cytotoxic killing to only occur within the solid tumor microenvironment.
To view VY-GAGE mechanism-of-action video, please visit:
(Press release, Vycellix, JUN 4, 2026, View Source;utm_medium=rss&utm_campaign=vycellix-to-provide-universal-cell-cancer-therapy-progress-reports-at-upcoming-investor-partnering-meetings [SID1234666440])